Despite the setbacks, interest in TGF-β remains
Novartis looks set to hand nisevokitug rights back to Xoma, though plenty of work on TGF-β continues.
Novartis looks set to hand nisevokitug rights back to Xoma, though plenty of work on TGF-β continues.
Flaura2 takes centre stage, while Trodelvy and dato square off in PD-1 combo trials.